# Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

> **NCT01101035** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 6198 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT01101035
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-23
- **Primary completion:** 2017-05-15
- **Final completion:** 2017-07-18
- **Target enrollment:** 6198 (ACTUAL)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101035, "Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)". Retrieved via MORVS 2026-10-01 from https://api.morvs.ai/clinical/NCT01101035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*